Samsung Bioepis and Genentech Settles Patent Dispute of Trastuzumab Biosimilar-Ontruzant
Shots:
- Samsung Bioepis and Genentech has filed a joint stipulation of dismissal of their BPCIA patent litigation for Ontruzant- a biosimilar of Herceptin
- Under the settlement and license agreement- the companies jointly moved to voluntarily dismiss Bioepis’ appeal of the PTAB’s decisions upholding the patentability of U.S. Patent nos. 6-627-196 & 7-371-379- directed to cancer therapies. The agreement allows Bioepis to commercialize the Ontruzant in the US
- Ontruzant is biosimilar of trastuzumab targeting HER2 receptor- indicated for HER2-overexpressing breast cancer and m-gastric cancer marketed by Merck in the US and has received approval in the US & EU in Nov’2017 & Jan’2019 respectively
Click here to read full press release/ article
Ref: US District Court | Image: Samsung Bioepis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com